This study looked at a few confirmed cases of chronic lymphocytic leukemia (CLL) that may have had mutations in the human B lymphocyte genome's P-53 gene. The ELISA technique was used to determine the frequency of p-53 protein expression in twenty CLL patients undergoing evaluation in stages II–III / IV. In 17 of the 20 cases, the average amounts of p-53 proteins were found to be 16.76 μg/dl, with a probability index of p = 0.034 and a CV of 0.5%. It was discovered that as the illness progressed, the proportion of p-53 positive isoform proteins rose above normal. The percentage was 15% ± 2 in stages 1-2 and 100% in stages 3-4. Recent studies have shown that the p-53 protein inhibits protein kinase B, the AMPK protein, and the mTOR complex, hence mediating genes that trigger autophagy and stimulating autophagy. One potential use of the p-53 protein's role in cancer cell autophagy is the development of a novel anti-cancer medicinal approach. When a patient develops resistance to the initial line of treatment, the ELISA approach has shown to be an invaluable prognostic tool for CLL, enabling the administration of customized medication.